



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the use of Rituximab (Rituxan®) as Maintenance Therapy  
for Low-Grade Non-Hodgkin's Lymphoma (NHL)**

**Approved Use:**

**Rituximab Maintenance:** As a **single agent** in patients with documented evidence of CD20+ low-grade NHL (excluding SLL), with an ECOG performance status of 0-2, who have received rituximab within the previous six months either as a single agent or as part of multi-agent chemotherapy, responded to that therapy, have a recommendation and choose to receive maintenance therapy. Patients would only be eligible for rituximab maintenance following their first exposure to a rituximab based induction treatment regimen.

- This policy recommendation represents a **new guideline document** and a restriction of rituximab as maintenance therapy to include patients who have received rituximab monotherapy or as part of the multi-agent chemotherapy and responded to that therapy. Patients would only be eligible following their first exposure to a rituximab based induction treatment regimen.